These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 18718209)

  • 1. [Involvement of central neurotransmission systems in schizophrenia].
    Martres MP
    Therapie; 2008; 63(3):177-85. PubMed ID: 18718209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of central glutamatergic neurotransmission in the pathogenesis of psychiatric and behavioral disorders.
    Wang SJ; Yang TT
    Drug News Perspect; 2005 Nov; 18(9):561-6. PubMed ID: 16421629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Glutamatergic neurotransmission in schizophrenics].
    Bleich S; Bleich K; Wiltfang J; Maler JM; Kornhuber J
    Fortschr Neurol Psychiatr; 2001 Sep; 69 Suppl 2():S56-61. PubMed ID: 11533851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The neurobiology of schizophrenia.
    Littrell RA; Schneiderhan M
    Pharmacotherapy; 1996; 16(6 Pt 2):143S-147S; discussion 166S-168S. PubMed ID: 8947997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glutamatergic neurotransmission modulators as emerging new drugs for schizophrenia.
    Heresco-Levy U
    Expert Opin Emerg Drugs; 2005 Nov; 10(4):827-44. PubMed ID: 16262565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serotonin-dopamine interaction: an overview.
    Esposito E; Di Matteo V; Di Giovanni G
    Prog Brain Res; 2008; 172():3-6. PubMed ID: 18772025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How do glial-neuronal interactions fit into current neurotransmitter hypotheses of schizophrenia?
    Kondziella D; Brenner E; Eyjolfsson EM; Sonnewald U
    Neurochem Int; 2007 Jan; 50(2):291-301. PubMed ID: 17084946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Current status of biochemical hypotheses in the pathogenesis of schizophrenia].
    Kornhuber J; Weller M
    Nervenarzt; 1994 Nov; 65(11):741-54. PubMed ID: 7816150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hypoglutamatergic hypothesis of schizophrenia: evidence from genetic studies].
    Itokawa M; Yoshikawa T
    Seishin Shinkeigaku Zasshi; 2003; 105(11):1349-62. PubMed ID: 14758783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The dopamine system and the pathophysiology of schizophrenia: a basic science perspective.
    Goto Y; Grace AA
    Int Rev Neurobiol; 2007; 78():41-68. PubMed ID: 17349857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathophysiologically based treatment interventions in schizophrenia.
    Lewis DA; Gonzalez-Burgos G
    Nat Med; 2006 Sep; 12(9):1016-22. PubMed ID: 16960576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alterations of serotonin transmission in schizophrenia.
    Abi-Dargham A
    Int Rev Neurobiol; 2007; 78():133-64. PubMed ID: 17349860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reviewing the role of the genes G72 and DAAO in glutamate neurotransmission in schizophrenia.
    Boks MP; Rietkerk T; van de Beek MH; Sommer IE; de Koning TJ; Kahn RS
    Eur Neuropsychopharmacol; 2007 Sep; 17(9):567-72. PubMed ID: 17250995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Structural and functional organization of the cerebral dopaminergic system].
    Barishpolets VV; Fedotova IuO; Sapronov NS
    Eksp Klin Farmakol; 2009; 72(3):44-9. PubMed ID: 19642593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Central organization of transmitter systems].
    Cuénod M; Reubi JC
    Schweiz Arch Neurol Neurochir Psychiatr; 1979; 125(2):205-15. PubMed ID: 45340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The dopamine dysfunction in schizophrenia revisited: new insights into topography and course.
    Kuepper R; Skinbjerg M; Abi-Dargham A
    Handb Exp Pharmacol; 2012; (212):1-26. PubMed ID: 23129326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serotonin control of central dopaminergic function: focus on in vivo microdialysis studies.
    Di Matteo V; Di Giovanni G; Pierucci M; Esposito E
    Prog Brain Res; 2008; 172():7-44. PubMed ID: 18772026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Schizophrenia as a dynamical disease.
    an der Heiden U
    Pharmacopsychiatry; 2006 Feb; 39 Suppl 1():S36-42. PubMed ID: 16508894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glutamatergic neurotransmission involves structural and clinical deficits of schizophrenia.
    Tsai G; van Kammen DP; Chen S; Kelley ME; Grier A; Coyle JT
    Biol Psychiatry; 1998 Oct; 44(8):667-74. PubMed ID: 9798069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loudness dependence of the auditory evoked N1/P2 component as an indicator of serotonergic dysfunction in patients with schizophrenia--a replication study.
    Juckel G; Gudlowski Y; Müller D; Ozgürdal S; Brüne M; Gallinat J; Frodl T; Witthaus H; Uhl I; Wutzler A; Pogarell O; Mulert C; Hegerl U; Meisenzahl EM
    Psychiatry Res; 2008 Feb; 158(1):79-82. PubMed ID: 18096246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.